药物临床试验中受试者权益保护机制的探讨

来源 :上海食品药品监管情报研究 | 被引量 : 0次 | 上传用户:seanyx
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
药物临床试验,是新药研发中的重要环节,临床试验的科学准确,决定着创新药物是否能成功开发上市。所以,加强对药品研究过程中临床试验的监督管理,是越来越受关注的话题。过程监管不仅是关注研究进展全过程的规范性,更要关注在研究过程中受试者的权益保护问题。由于我国在药物临床试验管理方面相关的法规起步较晚,本课题将通过对药物临床试验中伦理审查管理模式的探讨、儿童用创新药物的知情同意如何完善以及如何建立在药物临床试验中的意外伤害保险制度等,探索更好地健全药物临床试验中受试者的权益保护机制。 Drug clinical trials, research and development of new drugs is an important part of clinical trials of scientific and accurate, determines whether the successful development of innovative drugs listed. Therefore, to strengthen the supervision and management of clinical trials in the process of drug research is a topic of increasing concern. Process supervision is not only concerned about the normative nature of the whole process of research progress, but also focuses on the subjects' rights and interests protection during the research process. Because of the late start of the relevant laws and regulations on drug clinical trial management in our country, this subject will discuss the management mode of ethical examination in drug clinical trials, how to improve the informed consent of children with innovative drugs and how to establish the accident in drug clinical trials Injury insurance system, to explore and better improve the clinical trials of drug subjects' rights and interests protection mechanism.
其他文献
在北洋政府的5任总统中,徐世昌是惟一的文职总统。他曾任清廷翰林院编修,因而被人们称为“翰林总统”。他能作好诗能撰好文能写好字能绘好画,因此在清末民初的艺坛上尽领风骚。其充满爱国忠贞精神的晚年,更值得人们敬佩。  1922年5月底,68岁的徐世昌被迫离开坐了三年零九个月的总统宝座,从北京迁居天津英国租界,开始了几乎与世隔绝的“寓公”生活。  徐世昌下野之后,从不阅览报刊杂志,只是由曾任总统府收支处长